Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Teratogenicity01:07

Teratogenicity

2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Development of Immunocompetence01:22

Development of Immunocompetence

294
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
294
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

143
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
143
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

241
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
241

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Provider Perspectives to Inform a Patient-Facing Decision Aid on Oral Corticosteroid Use During Pregnancy and Evaluation of the Aid.

Pharmacoepidemiology and drug safety·2026
Same author

Flexible Multifunctional Composite Phase Change Materials for Enhanced Thermal Safety of Battery Energy Storage Systems.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Leveraging Molecular Weight Dispersity for Scalable, Precise Synthesis of Nanocylinders Via Quasi-Polymerization-Induced Self-Assembly.

Angewandte Chemie (International ed. in English)·2026
Same author

Effect of Different Carbon-Supported Catalysts on the Thermal Decomposition of Energetic Thermoplastic Elastomers.

Materials (Basel, Switzerland)·2026
Same author

The Built-in Electric Field in Bimetallic System Promotes the Efficient Thermal Decomposition of Ammonium Perchlorate.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

46th Annual David W. Smith Workshop on Malformations and Morphogenesis.

American journal of medical genetics. Part A·2026

相关实验视频

Updated: Jun 13, 2025

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
09:09

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring

Published on: August 17, 2022

1.6K

在怀孕期间服用维多利祖马布的妇女的分娩结果:来自维多利祖马布怀孕暴露注册表的结果.

Christina D Chambers1,2, Diana L Johnson1, Yunjun Luo1

  • 1Department of Pediatrics, University of California San Diego, La Jolla, CA.

The American journal of gastroenterology
|June 11, 2025
PubMed
概括

这项研究发现,维多利祖马布 (一种生物疗法) 是克罗恩病和性结肠炎在怀孕期间的安全治疗选择. 对于重大出生缺陷或其他不良妊娠结果,没有观察到重大风险.

关键词:
克罗恩氏病是什么疾病出生缺陷 产生的缺陷怀孕 怀孕 怀孕 怀孕 怀孕登记处的注册表可以看到.在安全方面,安全是安全的.性结肠炎是一种我已经看到了Vedolizumab.

更多相关视频

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.7K
Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

26.3K

相关实验视频

Last Updated: Jun 13, 2025

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
09:09

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring

Published on: August 17, 2022

1.6K
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.7K
Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

26.3K

科学领域:

  • 胃肠病学 胃肠病学
  • 免疫学 免疫学 免疫学
  • 生殖医学 生殖医学

背景情况:

  • 关于怀孕期间在炎症性肠病 (IBD) 时的vedolizumab安全性的数据有限.
  • 维多利祖马布是一种用于克罗恩病和性结肠炎的生物疗法.
  • 怀孕登记册对于评估怀孕期间药物安全性至关重要.

研究的目的:

  • 评估怀孕期间在IBD的妇女中暴露于韦多利祖马布的安全性.
  • 为了比较视多利祖马布暴露和未暴露的队列之间的怀孕和婴儿结局.
  • 为临床医生和患者提供关于怀孕时使用vedolizumab的基于证据的信息.

主要方法:

  • 展望性,观察性怀孕登记研究 (2015-2022) 涉及275名孕妇.
  • 三个队列:暴露于韦多利祖马布 (N=99),与疾病相匹配的生物暴露 (N=76) 和未暴露 (N=100).
  • 产后一年的随访,评估重大/小的出生缺陷,流产,早产,生长,感染,恶性瘤和发育.

主要成果:

  • 没有统计学上显著的重大出生缺陷 (aRR 1.07) 或自发流产 (aHR 1.01) 的风险增加与vedolizumab暴露.
  • 在vedolizumab组观察到的早产的轻微,无意义的增加 (aHR 1.58).
  • 没有发现其他研究结果的显著增加风险,包括产后生长和感染.

结论:

  • 在怀孕期间暴露于维多利祖马布似乎是安全的治疗克罗恩病和性结肠炎.
  • 这项研究提供了令人放心的证据,支持在孕妇IBD患者中使用vedolizumab.
  • 进一步的研究可能会继续监测长期结果,但目前的数据是有利的.